The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing outcomes of biliary tract cancers (BTC) with β-catenin (CTNNB1) alterations.
 
Lydia D. Chow
No Relationships to Disclose
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Agenus (Inst); Dragonfly Therapeutics (Inst); Indaptus Therapeutics (Inst); Toray Industries (Inst); Xilio Therapeutics (Inst)
 
Rituparna Ganguly
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Yasmine Baca
Employment - Caris Life Sciences
 
Jonathan Pai
No Relationships to Disclose
 
Ani Misirian
No Relationships to Disclose
 
Sandra Algaze
No Relationships to Disclose
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; Incyte; Ipsen; Isofol Medical; QED Therapeutics; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Philip A. Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Syma Iqbal
Honoraria - Astellas Scientific and Medical Affairs Inc; AstraZeneca; BeiGene; BMSi; Merck
Consulting or Advisory Role - AstraZeneca; BeiGene; BMS; Merck
Travel, Accommodations, Expenses - Astellas Pharma
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics